KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Other Non-Current Liabilities (2016 - 2025)

AbbVie (ABBV) has disclosed Other Non-Current Liabilities for 14 consecutive years, with $32.6 billion as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 8.1% to $32.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $32.6 billion through Dec 2025, up 8.1% year-over-year, with the annual reading at $32.6 billion for FY2025, 8.1% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $32.6 billion at AbbVie, up from $31.7 billion in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $32.6 billion in Q4 2025, with the low at $12.5 billion in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $20.7 billion, with a median of $18.9 billion recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 82.5% in 2021, then fell 2.43% in 2022.
  • Over 5 years, Other Non-Current Liabilities stood at $14.9 billion in 2021, then rose by 10.06% to $16.4 billion in 2022, then increased by 21.4% to $19.9 billion in 2023, then soared by 51.48% to $30.1 billion in 2024, then increased by 8.1% to $32.6 billion in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $32.6 billion, $31.7 billion, and $32.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.